TOC 50

Drug Profile

TOC 50

Latest Information Update: 15 Jun 2001

Price : $50

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antibacterials; Cephalosporins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 15 Jun 2001 No-Development-Reported for Bacterial infections in Japan (Parenteral)
  • 01 May 1997 An animal study has been added to the Bacterial infections pharmacodynamics section
  • 30 Jan 1997 An in vitro and an animal study have been added to the antimicrobial activity and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top